Remove 2015 Remove Clinical Trials Remove Patients Remove Safety
article thumbnail

July 18: Patient safety issues halt trial for MDMA-assisted psychotherapy during Health Canada review

Cannabis Law Report

Patient safety concerns uncovered during an ongoing federal review have led to the suspension of one of two clinical trials for MDMA-assisted psychotherapy currently underway in Canada. A spokesperson told CBC in an email that the study was put on hold “due to concerns for participant safety.”

Safety 52
article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. It is estimated that, in 2015, 3% of people in the UK were living with PTSD. Berra Yazar-Klosinski, Ph.D.

Therapy 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Cannabis Law Report

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector. The good news is that innovations that completely change the lives of patients continue to emerge. David Nutt and Prof.

Access 52
article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,

Safety 45
article thumbnail

Skin Cancer Drugs Global Market Report 2021: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma – ResearchAndMarkets.com

Cannabis Law Report

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Global Skin Cancer Drugs Historic Market, 2015-2020, $ Billion. Skin Cancer Drugs Market Size And Growth. Actinic Keratoses (AK).

article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. improvement in good sleep.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.